In addition to hepassocin's role in the development of NAFLD, the hepassocin promoter is transcriptionally upregulated through an IL-6/IL-6R/STAT3 signaling pathway, which maintains metabolic homeostasis 33. Here, FGL1 is linked to metabolic dysfunction-associated steatotic liver disease.